论文部分内容阅读
目的:探讨左炔诺孕酮宫内缓释系统(LNG-IUS;商品名:曼月乐)治疗子宫腺肌病的临床疗效。方法:对56例要求保留子宫的子宫腺肌病患者进行放置LNG-IUS,观察患者放环(LNG-IUS)前后痛经程度、月经量、子宫大小、子宫内膜厚度与血清CA125水平的变化。结果:放环后1、3、6个月随访,患者月经量明显减少,与放环前比较差异有统计学意义(P<0.05);痛经明显减轻,与放环前比较差异有统计学意义(P<0.01);子宫体积不同程度缩小,与放环前比较差异有统计学意义(P<0.05或P<0.01);子宫内膜厚度明显变薄、血清CA125水平显著下降,与放环前比较差异有统计学意义(P<0.05)。结论:LNG-IUS治疗子宫腺肌病是一种安全、有效的新方法。
Objective: To investigate the clinical efficacy of levonorgestrel-releasing intrauterine system (LNG-IUS; trade name: Mirena) in the treatment of adenomyosis. Methods: LNG-IUS was placed in 56 cases of adenomyosis requiring retention of uterus, and the changes of dysmenorrhea, menstrual flow, uterine size, endometrial thickness and serum CA125 level before and after LNG-IUS were observed. Results: After 1,3,6 months of follow-up, the menstrual volume of patients decreased significantly compared with that before release (P <0.05), and the dysmenorrhea was significantly reduced (P <0.01). The volume of uterus contracted to varying degrees with statistical significance (P <0.05 or P <0.01). The thickness of endometrium was thinner and the level of serum CA125 was significantly decreased. The difference was statistically significant (P <0.05). Conclusion: LNG-IUS treatment of adenomyosis is a safe and effective new method.